ACAD ACADIA Pharmaceuticals Inc.

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Latest News

1. 03 March 2020 ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Rare Pediatric Disease Designation for Trofinetide for the Treatment of Rett Syndrome

   With No Approved Treatments in Rett Syndrome, FDA Decision Highlights Significant Unmet Need ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) and Neuren Pharmaceuticals Limited (ASX: NEU) announced today that the U.S. Food

2. 26 February 2020 ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results

   - Full Year 2019 Net Sales Grew to $339.1 Million, a 52% Increase over Full Year 2018 - 2020 Net Sales Guidance of $440 to $470 Million - On-Track to Submit Supplemental New Drug Application for Dementia-Related

3. 24 February 2020 ACADIA Pharmaceuticals to Present at the Cowen and Company 40th Annual Health Care Conference on March 2, 2020

   ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), today announced that it will present at the Cowen and Company 40th Annual Health Care Conference in Boston on Monday, March 2, 2020, at 2:10 p.m. Eastern Time. A live webcast

4. 12 February 2020 ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results on February 26, 2020

   ACADIA to Host Conference Call and Webcast on Wednesday, February 26, 2020, at 5:00 p.m. Eastern Time ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that it will report fourth quarter and full year 2019

5. 07 January 2020 ACADIA Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference on January 14, 2020

   ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous

6. 18 December 2019 ACADIA Pharmaceuticals Appoints Stephanie Fagan as Senior Vice President, Corporate Affairs and Chief Communications Officer

   ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that Stephanie Fagan has been appointed to the newly created position of Senior Vice President, Corporate Affairs and Chief Communications Officer. Ms. Fagan

7. 04 December 2019 ACADIA Pharmaceuticals Presents Positive Top-line Results from Pivotal Phase 3 HARMONY Trial of Pimavanserin in Patients with Dementia-Related Psychosis at 12th Clinical Trials on Alzheimer's Disease (CTAD) Meeting

   - Pimavanserin met the primary endpoint in the study, significantly reducing the risk of relapse of psychosis by 2.8 fold (Hazard Ratio (HR)=0.353, one-sided p=0.0023) - Pimavanserin met the key secondary endpoint in

8. 25 November 2019 ACADIA Pharmaceuticals Announces Positive Top-line Results from ADVANCE Trial of Pimavanserin as Treatment for Negative Symptoms of Schizophrenia

   - ACADIA to initiate second pivotal study in the first half of 2020 - Conference call and webcast to be held today at 5:00 p.m. Eastern Time ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), today announced positive

9. 11 November 2019 ACADIA Pharmaceuticals to Host Investor Event and Webcast From Clinical Trials on Alzheimer's Disease (CTAD) Meeting on December 4, 2019

   ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), today announced it will host a live webcast of its investor event following the late-breaking oral presentation of the Phase 3 HARMONY results evaluating pimavanserin as a

10. 04 November 2019 ACADIA Pharmaceuticals Appoints Ponni Subbiah, M.D., M.P.H., as Senior Vice President, Global Head of Medical Affairs and Chief Medical Officer

    ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) today announced the appointment of Ponni Subbiah, M.D., M.P.H., as Senior Vice President, Global Head of Medical Affairs and Chief Medical Officer. Dr. Subbiah will report to

11. 30 October 2019 ACADIA Pharmaceuticals Initiates Phase 3 Pivotal Study of Trofinetide in Rett Syndrome, a Rare Neurodevelopmental Congenital CNS Disorder

    ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders,

12. 30 October 2019 ACADIA Pharmaceuticals Reports Third Quarter 2019 Financial Results

    - 3Q19 Net Sales Grew to $94.6 Million, a 62% Increase Over 3Q18 - 2019 Net Sales Guidance Increased to $330 to $340 Million - Initiated Phase 3 LAVENDER Study of Trofinetide in Rett Syndrome, a Rare

13. 07 October 2019 ACADIA Pharmaceuticals Presents Additional Positive Data from the Phase 2 CLARITY Study with Pimavanserin in Adjunctive Major Depressive Disorder at 2019 Psych Congress

    — Pimavanserin as adjunctive treatment to SSRI/SNRI therapies significantly improved sexual dysfunction symptoms compared to placebo in MDD patients ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that based

14. 03 October 2019 ACADIA Pharmaceuticals Announces Late-Breaking Oral Presentation of the Phase 3 HARMONY Study of Pimavanserin in Dementia-Related Psychosis at the Clinical Trials on Alzheimer's Disease (CTAD) 2019 Meeting

    ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that the presentation of the results from the Phase 3 HARMONY study of pimavanserin in dementia-related psychosis has been accepted for a late-breaking oral

15. 25 September 2019 ACADIA Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference on October 2, 2019

    ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today

16. 24 September 2019 ACADIA Pharmaceuticals Announces that The Journal of Clinical Psychiatry Publishes Positive Phase 2 CLARITY Results for Pimavanserin as Adjunctive Treatment for Patients with Major Depressive Disorder

    - Pimavanserin as an adjunctive treatment for patients with MDD showed significant overall improvement in HAMD-17 total score compared to placebo - Phase 3 CLARITY program initiated in April 2019 ACADIA

17. 23 September 2019 ACADIA Pharmaceuticals Presents New Data on PD Patients Treated with Pimavanserin for Depression at the 2019 International Congress of Parkinson's Disease and Movement Disorders

    - Pimavanserin as monotherapy or adjunct to SSRI/SNRI therapies significantly improved depression symptoms for Parkinson's patients ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) today announced positive results from an

18. 20 September 2019 ACADIA Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

    ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders,

19. 19 September 2019 ACADIA Pharmaceuticals to Present New Clinical Data and Outcomes Research at Upcoming Scientific Meetings

    — New data presented at the International Congress of Parkinson's Disease and Movement Disorders will highlight treatment benefit of pimavanserin in patients with comorbid Parkinson's disease and depression — New data

20. 17 September 2019 ACADIA Pharmaceuticals Prices Public Offering of Common Stock

    ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders,

21. 17 September 2019 ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock

    ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders,

22. 10 September 2019 Thinking about buying stock in Acadia Pharmaceuticals, Aurora Cannabis, Bank of America, SINTX Technologies, or AT&T?

    NEW YORK, Sept. 9, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACAD, ACB, BAC, SINT, and T. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the

23. 09 September 2019 ACADIA Pharmaceuticals Announces Pivotal Phase 3 HARMONY Trial Stopped Early for Positive Efficacy as Pimavanserin Meets the Primary Endpoint in Patients with Dementia-Related Psychosis

    - Pimavanserin achieved robust statistical superiority over placebo in time to relapse of dementia-related psychosis at planned interim efficacy analysis - Pimavanserin has the potential to be the first FDA-approved

24. 04 September 2019 ACADIA Pharmaceuticals to Present at the Morgan Stanley 17th Annual Global Healthcare Conference on September 11, 2019

    ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today